Board of Directors

Toby Wilson Waterworth(BSc (Econ), FCA)

Chief Executive Officer

Senior management expertise in successfully building and growing healthcare companies including Robannic NV, Chiroscience Group plc (LSE), (acquired by Celltech Group plc (LSE)), Alizyme plc (LSE & AIM), Expedean (acquired by Sygnis AG) and Xenetic Biosciences (NASDAQ: XBIO), formerly Lipoxen plc.

Toby is a Fellow of the Institute of Chartered Accountants in England and Wales, Fellow of the Royal Society of Medicine, and former advisor to the UK government in the development and commercialisation of healthcare innovations.

Thomas Wellner(BSc)

Chairman, Non-Executive Director

Tom is President and CEO of Canada based Revera, a leading provider of seniors’ accommodation, care and services, owned by Canada’s Public Sector Pension Investment Board.

He has extensive leadership experience in the healthcare sector including CEO of CML Healthcare Inc, (acquired by LifeLabs Medical Laboratories for $1.2 bn) and 20 years with Eli Lilly & Co in senior roles in North and South America, and Europe.

William Ringo(MBA)

Non-Executive Director

Bill is an eminent pharma veteran with nearly 30 years experience of public markets, M&A, product commercialisation, and financial institutions.

He is currently Chairman of Assembly Biosciences Inc., and a director of Sangamo Therapeutics Inc., Immune Design Corp., Dermira Inc., and Five Prime Therapeutics Inc..

Previous roles include Chairman, CEO and President of NASDAQ-listed InterMune, Inc; SVP of Strategy and Business Development at Pfizer, Inc.; President and CEO of NASDAQ-listed Abgenix, Inc. Bill was also a member of Eli Lilly and Company’s operating committee.

Charles Woler(MD, PhD)

Non-Executive Director

Charles Woler has spent the last 30 years in the healthcare industry, both in large multinational pharmaceutical companies and smaller, earlier stage companies.

He currently holds non-executive Chairman and non-executive Director positions in Europe and the U.S..

Previously Charles was Chairman and CEO of Roche France, Chairman of SmithKline Beecham’s European pharmaceutical business (UK), CEO of Cadus Pharmaceuticals (U.S.) and CEO of Biomnis (France).

Andrew Boyce

Non-Executive Director

Since 1987, Andrew has managed a private family office, which has diverse commercial interests including technology and medical investments, property, and farming. Andrew represents a significant shareholding in Atlantic Healthcare for the family office, and was one of the founding investors in 2006. He is a member of the board of UK AIM-listed Hardide plc, a novel chemicals and coatings technology company, where he has served as a non-executive director since June 2012.